Paul Cayer Net Worth

The estimated Net Worth of Paul E Cayer is at least $954 Тысяча dollars as of 25 March 2022. Mr. Cayer owns over 9,639 units of Otonomy Inc stock worth over $17,232 and over the last 10 years he sold OTIC stock worth over $23,134. In addition, he makes $913,957 as Chief Financial and Business Officer at Otonomy Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cayer OTIC stock SEC Form 4 insiders trading

Paul has made over 6 trades of the Otonomy Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 9,639 units of OTIC stock worth $23,134 on 25 March 2022.

The largest trade he's ever made was selling 9,639 units of Otonomy Inc stock on 25 March 2022 worth over $23,134. On average, Paul trades about 1,369 units every 132 days since 2014. As of 25 March 2022 he still owns at least 223,787 units of Otonomy Inc stock.

You can see the complete history of Mr. Cayer stock trades at the bottom of the page.

Paul Cayer biography

Paul E. Cayer is Chief Financial and Business Officer of the Company. Mr. Cayer brings more than 25 years of experience in the pharmaceutical, medical device and healthcare technology field. Prior to joining our company, Mr. Cayer served from 2005 to 2008 as Senior Vice President, Corporate Development for Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children. Mr. Cayer has also held various management positions with Targeted Molecules Corporation, a biopharmaceutical company, Gensia Pharmaceuticals, Inc., a biopharmaceutical company, Acuson, a provider of medical ultrasound systems, Castle & Cooke, a consumer products company, and served as consultant with Booz-Allen & Hamilton, a management and technology consulting firm. Mr. Cayer received his MBA and Bachelor’s degree in biomechanical engineering from Harvard University.

What is the salary of Paul Cayer?

As the Chief Financial and Business Officer of Otonomy Inc, the total compensation of Paul Cayer at Otonomy Inc is $913,957. There are 2 executives at Otonomy Inc getting paid more, with David Weber having the highest compensation of $2,153,120.

How old is Paul Cayer?

Paul Cayer is 58, he's been the Chief Financial and Business Officer of Otonomy Inc since 2015. There are 7 older and 4 younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.

What's Paul Cayer's mailing address?

Paul's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.

Insiders trading at Otonomy Inc

Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo и Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.

What does Otonomy Inc do?

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.

Complete history of Mr. Cayer stock trades at Otonomy Inc

Otonomy Inc executives and stock owners

Otonomy Inc executives and other stock owners filed with the SEC include:

• David Weber,
  President, Chief Executive Officer, Director
• Dr. David Allen Weber,
  Pres, CEO & Director
• Paul Cayer,
  Chief Financial and Business Officer
• Robert Savel,
  Chief Technical Officer
• Paul E. Cayer,
  Chief Financial & Bus. Officer
• Robert Michael Savel II,
  Chief Technical Officer
• Jay Lichter,
  Independent Chairman of the Board
• Vickie Capps,
  Independent Director
• Iain McGill,
  Independent Director
• James Breitmeyer,
  Independent Director
• Theodore Schroeder,
  Independent Director
• Dr. Jay B. Lichter Ph.D.,
  Co-Founder & Independent Chairman
• Ciara Kennedy,
  Independent Director
• James Branch CPA,
  VP of Fin. & Controller
• David Skarinsky,
  Sr. VP of Clinical
• Breianna Bowen,
  VP of HR
• Fabrice Piu Ph.D.,
  Sr. VP of Preclinical Devel.
• Barbara M. Finn,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Alan Charles Foster Ph.D.,
  Chief Scientific Officer
• Julie D. Burgess,
  VP of Fin. & Admin.
• Dr. Rick Adam Friedman M.D., Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Dr. Allen F. Ryan Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Katherine Mary Bishop,
  Chief Scientific Officer
• Eric J Loumeau,
  GC & Chief Compliance Officer
• Carl Le Bel,
  Chief Scientific Officer
• Heather Preston,
  Director
• George J Morrow,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Chau Quang Khuong,
  Director
• Anthony J Yost,
  Chief Commercial Officer
• Dean Hakanson,
  Chief Medical Officer
• John P Mckearn,
  Director
• Partners Viii, L.P.Blair Ja...,
  
• Ventures Viii Lp Avalon Ven...,
  
• Holdings A/S Novo,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Viii Associates, L.P.Domain...,
  
• Alan Charles Foster,
  Chief Scientific Officer
• Brian H Dovey,
  Director
• Jill Marie Broadfoot,
  Director